Grifols A : Assessing fresh consent solicitation request and impact from GIC transaction
Grifols sent last Friday a consent solicitation request to bondholders, asking them to release the guarantee granted by US-based plasma collection unit Biomat USA on the notes as well as the security interest in the shares of this subsidiary. The request stems from the planned disposal of 23.8% of US-based plasma collection unit Biomat to Singapore's sovereign fund GIC. Bondholders will receive a consent fee of 25bps if they accept the waiver with a deadline set for tomorrow 6 Au...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.